BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,777.70
- Market cap
- ₹4,26,530 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 35.3×Sector 45.9×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Other annual general meeting announcements
All →TeleCanor Global Annual General Meeting
TeleCanor Global held its 34th AGM on 31-Oct-2026 and the proceedings were filed with the exchange. Two ordinary resolutions were put to members, covering adoption of FY2026 accounts and re-appointment of a retiring director.
Bondada Engineering Annual General Meeting
Bondada Engineering Ltd has called an extraordinary general meeting on 21 November 2026. Shareholders will vote on related-party loans, security creation and borrowing limits.
Uflex Annual General Meeting
Uflex shareholders approved a special resolution to borrow up to ₹5,000 Crore under Section 180(1)(c) via postal ballot, with 99.92% in favour. The result was declared on 31 October 2026.
Stovec Industries Annual General Meeting
Stovec Industries' shareholders approved two non-executive director appointments by postal ballot. Both resolutions passed with about 98% of votes polled in favour.
Innovators Facade Systems Annual General Meeting
EOGM on 25 Nov 2026 seeks approval for 9,50,971 preferential shares and a related-party share acquisition. Transaction value is Rs 11.22 Crore.
- Value
- ₹11.22 Cr
- Execution
- 25-11-2026 to 24-05-2027
Aesthetik Engineers Annual General Meeting
Aesthetik Engineers has issued notice for its Annual General Meeting on 28 November 2026 by video conference. Shareholders will vote on adopting FY2025 financial statements and two director appointments.